Astrazeneca Ab

Paul Robert Owen Whittamore

Andrew Stocker

James Stewart Scott

Martin John Packer

Andrew David Morley

William McCoull

Alan Martin Birch

Iain Simpson

Gary Peter Tomkinson

Rodney Brian Hargreaves

Stuart Norman Lile Bennett

Martin Packer

Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11&#x3b2;HSD1, processes for making them and pharmaceutical compositions comprising them are described.

Chemical compounds

A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11&#x3b2;HSD1, processes for making them and pharmaceutical compositions comprising them are also described.

Pyrazole derivatives as 11-beta-HSD1 inhibitors

New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11&#x3b2;HSD1, processes for making them and pharmaceutical compositions comprising them are also described.

Crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic acid 471

Heterocyclic amides of formula (1) and pharmaceutically acceptable salts or pro-drugs thereof wherein variable groups are as described herein; which possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity are described. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are also described.

Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity

Heterocyclic amides of formula (1) wherein:

Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase

Indolamid derivatives which possess glycogenphosphorylase inhibitory activity

Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase

The present invention relates to the use of certain benzoic acid derivatives of formula (I), as disclosed in the specification, which act as peroxisome proliferator activated receptor (PPAR) agonists, in particular states of insulin resistance including type 2 gamma receptors (PPAR), and so are useful therapeutically in the treatment of diabetes mellitus. Novel pharmaceutical compositions and novel compounds are also defined, together with methods of their production.

Growing community of inventors

Macclesfield, United Kingdom

Paul Robert Owen Whittamore